SCHEDULE: Activist Investor Opposes Tiptree's Fortegra Sale

Veradace Capital Management, holding a 5% stake in Tiptree Inc., publicly opposes the proposed sale of its insurance subsidiary Fortegra to DB Insurance, citing undervaluation and tax inefficiencies.

Summary

• Veradace Capital Management LLC, Veradace Partners L.P., Alexander Vezendan, and John Conlin (the "Reporting Persons") collectively beneficially own 1,891,780 shares of Tiptree Inc. common stock, representing 5.0% of the outstanding shares.
• The Reporting Persons acquired these securities for investment purposes, with an aggregate purchase price of approximately $14,520,758, funded by working capital and margin accounts.
• They intend to vote against Tiptree's proposed sale of its insurance subsidiary, The Fortegra Group, Inc., to DB Insurance Co., Ltd. (the "Fortegra Transaction").
• Their opposition stems from beliefs that the Fortegra Transaction undervalues Fortegra, creates tax inefficiencies for Tiptree stockholders, and allows Tiptree to retain nearly $1 billion in proceeds for undisclosed purposes while management continues to collect compensation.
• Veradace previously offered to invest $50 million to $75 million in a potential Fortegra IPO, discussions which were not disclosed in Tiptree's definitive proxy statement.
• Veradace has formally communicated its concerns to Tiptree's independent directors, receiving a non-substantive reply from the Executive Chairman.
• The Fortegra Transaction was announced on September 26, 2025, with a special stockholder meeting scheduled for December 3, 2025, and an anticipated closing in mid-2026.

Sentiment

Score: 3

Explanation: The filing expresses strong negative sentiment regarding Tiptree's proposed Fortegra transaction, citing undervaluation, tax inefficiencies, and poor capital allocation decisions. The Reporting Persons are actively opposing the deal and raising corporate governance concerns.

Positives

• The Reporting Persons' engagement could potentially lead to a more favorable outcome for Tiptree shareholders if their concerns about undervaluation and tax inefficiencies are addressed.
• Veradace's prior offer to invest $50 million to $75 million in a Fortegra IPO indicates a belief in Fortegra's standalone value.

Negatives

• The proposed Fortegra Transaction is believed by the Reporting Persons to undervalue Fortegra.
• The transaction structure is considered tax-inefficient for Tiptree stockholders.
• Tiptree does not plan to distribute the nearly $1 billion in transaction proceeds to stockholders, instead holding it for undisclosed purposes.
• Tiptree management is expected to continue collecting compensation despite the sale.
• Tiptree's management and Board allegedly ignored Veradace's offers to support a Fortegra IPO and did not explore a sale of the entire Issuer.
• Discussions between Veradace and Tiptree management regarding a Fortegra IPO were not disclosed in the Issuer's definitive proxy statement.
• Tiptree's Executive Chairman provided a non-substantive reply to Veradace's letter outlining significant concerns.

Risks

• The Fortegra Transaction may proceed despite shareholder opposition, potentially locking in an undervalued sale and tax inefficiencies.
• Tiptree's retention of nearly $1 billion in proceeds for undisclosed purposes introduces uncertainty regarding future capital allocation.
• The lack of transparency regarding prior IPO discussions could raise corporate governance concerns.
• The transaction is not anticipated to close until mid-2026, subject to satisfaction of all closing conditions, introducing execution risk.

Future Outlook

The Reporting Persons intend to review their investment in Tiptree on an ongoing basis and may acquire or dispose of additional securities, or enter into hedging arrangements, depending on various factors including Tiptree's financial condition, the outcome of discussions, market conditions, and share prices. They also plan to continue communicating their views on the Fortegra Transaction and potential alternatives to the Board, management, and other shareholders, potentially through public materials.

Management Comments

• The Fund explained its intent to vote against the Merger Agreement and the reasons for its opposition, including that (i) the Fortegra Transaction undervalues Fortegra, (ii) the Fortegra Transaction subjects Issuer stockholders to tax inefficiencies, and (iii) Tiptree does not expect to distribute cash to its stockholders in connection with the Fortegra Transaction, instead holding nearly $1 billion in transaction proceeds for as-yet-undisclosed purposes and, presumably, allowing Issuer management to continue to collect compensation.
• Mr. Vezendan expressed Veradace's willingness to invest through affiliated entities $50 million to $75 million in such an IPO to help support a successful placement.
• Mr. Barnes sent a four sentence reply to Mr. Vezendan (the "Issuer Reply") that lacked any substantive response to the concerns or questions outlined in the Veradace Letter.

Industry Context

The filing highlights a common activist investor strategy where a significant shareholder publicly challenges a proposed corporate transaction, particularly a divestiture, believing it does not maximize shareholder value. This often occurs when a subsidiary is perceived to be undervalued in a sale, or when the parent company's post-transaction plans for proceeds are unclear or deemed unfavorable to shareholders. The offer to backstop an IPO suggests a belief that Fortegra could achieve a higher valuation as a standalone public entity, a common alternative to a direct sale.

Comparison to Industry Standards

• The Fortegra Transaction is valued at a "significant discount to comparable companies, based on a multiple of net income, according to the Issuer's own financial advisor." This suggests the deal falls below industry valuation benchmarks.
• The Reporting Persons' concerns about tax inefficiencies and the lack of cash distribution to shareholders contrast with best practices for maximizing shareholder returns in divestitures, where tax-efficient structures and direct returns of capital are often prioritized.

Corporate Governance

Stakeholder Impact

• Shareholders: Potential for a better outcome if Veradace's opposition leads to a revised or alternative transaction that maximizes value, or a worse outcome if the current transaction proceeds as is, leading to undervaluation and tax inefficiencies.
• Management: Increased scrutiny and pressure from an activist investor regarding strategic decisions, capital allocation, and compensation.
• Board of Directors: Increased pressure to justify the Fortegra Transaction and address corporate governance concerns raised by Veradace.
• Fortegra Group, Inc.: Its future ownership and strategic direction are under debate, potentially impacting its employees and operations depending on the transaction's outcome.

Next Steps

• The Reporting Persons intend to vote against the Fortegra Transaction at the special meeting on December 3, 2025.
• The Reporting Persons intend to bring the exclusion of their IPO discussions from the proxy statement to the attention of the SEC.
• The Reporting Persons may discuss a range of potential strategic alternatives for Tiptree with the Board, management, other shareholders, and third parties.
• The Reporting Persons may communicate their views publicly through open letters, press releases, or investor presentations.
• The Reporting Persons may acquire additional securities, dispose of existing securities, or enter into hedging arrangements based on ongoing review of their investment.
• The Fortegra Transaction is anticipated to close in mid-2026, assuming satisfaction of all closing conditions.

Key Dates

Recommendation

The filing details significant concerns from a 5% shareholder regarding the proposed sale of Tiptree's key asset, Fortegra. The activist investor argues the deal undervalues Fortegra, is tax-inefficient, and does not benefit shareholders through cash distribution, with proceeds instead retained for undisclosed purposes. This strong opposition, coupled with allegations of management ignoring better alternatives and a non-substantive response to shareholder concerns, suggests potential for significant downside if the current deal proceeds or if the company's governance issues persist. The uncertainty around the deal's outcome and the activist's intent to bring non-disclosures to the SEC further add to the negative outlook. An investor might consider selling to avoid potential value destruction or prolonged uncertainty.

Keywords

Tiptree Inc., Fortegra Group, DB Insurance, Veradace Capital Management, Schedule 13D, Activist Investor, Merger Opposition, Undervaluation, Tax Inefficiency, Corporate Governance, Shareholder Value, Insurance Subsidiary, Special Meeting, Proxy Solicitation